Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

946 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).
Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, Sun JH, Jin ZC, Chen JJ, Ge NJ, Ding WB, Li WH, Huang JH, Mu W, Gu SZ, Li JP, Zhao H, Wen SW, Lei YM, Song YS, Yuan CW, Wang WD, Huang M, Zhao W, Wu JB, Wang S, Zhu X, Han JJ, Ren WX, Lu ZM, Xing WG, Fan Y, Lin HL, Zhang ZS, Xu GH, Hu WH, Tu Q, Su HY, Zheng CS, Chen Y, Zhao XY, Fang ZT, Wang Q, Zhao JW, Xu AB, Xu J, Wu QH, Niu HZ, Wang J, Dai F, Feng DP, Li QD, Shi RS, Li JR, Yang G, Shi HB, Ji JS, Liu YE, Cai Z, Yang P, Zhao Y, Zhu XL, Lu LG, Teng GJ; CHANCE001 Investigators. Zhu HD, et al. Among authors: zhu xl, zhu x. Signal Transduct Target Ther. 2023 Feb 8;8(1):58. doi: 10.1038/s41392-022-01235-0. Signal Transduct Target Ther. 2023. PMID: 36750721 Free PMC article.
Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study.
Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Li J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Zhang Y, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Li X, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G; China HCC-TACE Study Group. Wang Q, et al. J Hepatol. 2019 May;70(5):893-903. doi: 10.1016/j.jhep.2019.01.013. Epub 2019 Jan 18. J Hepatol. 2019. PMID: 30660709
Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX, Wang EX, Bai W, Xia DD, Mu W, Li J, Yang QY, Huang M, Xu GH, Sun JH, Li HL, Zhao H, Wu JB, Yang SF, Li JP, Li ZX, Zhang CQ, Zhu XL, Zheng YB, Wang QH, Li J, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH, On Behalf Of China Hcc-Tace Study Group. Wang ZX, et al. Among authors: zhu xl. World J Gastroenterol. 2020 Feb 14;26(6):657-669. doi: 10.3748/wjg.v26.i6.657. World J Gastroenterol. 2020. PMID: 32103874 Free PMC article.
Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study.
Wang Z, Wang E, Bai W, Xia D, Ding R, Li J, Wang Q, Liu L, Sun J, Mu W, Zhao H, Pan X, Shao G, Zhu X, Yin G, Shi H, Wu J, Lin Z, Yang S, Liu J, Wang W, Zhu X, Lv Y, Li J, Chen H, Wang W, Li K, Yuan X, Yu T, Yuan J, Li X, Niu J, Yin Z, Xia J, Fan D, Han G. Wang Z, et al. Liver Cancer. 2020 Jun;9(3):308-325. doi: 10.1159/000505692. Epub 2020 Feb 19. Liver Cancer. 2020. PMID: 32647633 Free PMC article.
946 results